SEARCH

SEARCH BY CITATION

References

  • 1
    Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2717681.DOI: 10.1074/jbc.273.42.27176
  • 2
    Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 28559.
  • 3
    Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 215661.
  • 4
    Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 144551.DOI: 10.1001/jama.279.18.1445
  • 5
    Vogelvang TE, Leurs JR, Van Der Mooren MJ, Mijatovic V, Hendriks DF, Neele SJM, Netelenbos JC, Kenemans P. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women. Menopause 2004; 11: 1105.DOI: 10.1097/01.GME.0000097740.18446.77
  • 6
    Vogelvang TE, Mijatovic V, Kenemans P, Teerlink T, Van Der Mooren MJ. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertil Steril 2004; 82: 15409.DOI: 10.1016/j.fertnstert.2004.05.093
  • 7
    Vogelvang TE, Mijatovic V, Kenemans P, Schalkwijk CG, Van Der Mooren MJ. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women. Am J Cardiol 2004; 94: 12058.DOI: 10.1016/j.amjcard.2004.07.099
  • 8
    Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 84757.
  • 9
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women—results from the MORE randomized trial. JAMA 1999; 281: 218997.
  • 10
    Schatteman KA, Goossens FJ, Leurs JR, Kasahara Y, Scharpe SS, Hendriks DF. Fast homogeneous assay for plasma procarboxypeptidase U. Clin Chem Lab Med 2001; 39: 80610.DOI: 10.1515/CCLM.2001.133
  • 11
    Post MS, Hendriks DF, Van Der Mooren MJ, Van Baal WM, Leurs JR, Emeis JJ, Kenemans P, Stehouwer CDA. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized placebo-controlled 12-week study in early postmenopausal women. J Intern Med 2002; 251: 24551.DOI: 10.1046/j.1365-2796.2002.00960.x
  • 12
    Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003; 1: 120814.
  • 13
    Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs JR, Bouma B, Hendriks DF, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 11227.DOI: 10.1161/01.ATV.0000074145.58172.BD